全文获取类型
收费全文 | 2070篇 |
免费 | 115篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 74篇 |
妇产科学 | 24篇 |
基础医学 | 276篇 |
口腔科学 | 60篇 |
临床医学 | 212篇 |
内科学 | 413篇 |
皮肤病学 | 51篇 |
神经病学 | 149篇 |
特种医学 | 235篇 |
外国民族医学 | 1篇 |
外科学 | 246篇 |
综合类 | 41篇 |
预防医学 | 85篇 |
眼科学 | 13篇 |
药学 | 158篇 |
中国医学 | 6篇 |
肿瘤学 | 142篇 |
出版年
2023年 | 11篇 |
2021年 | 29篇 |
2020年 | 18篇 |
2019年 | 33篇 |
2018年 | 28篇 |
2017年 | 34篇 |
2016年 | 32篇 |
2015年 | 53篇 |
2014年 | 47篇 |
2013年 | 75篇 |
2012年 | 86篇 |
2011年 | 78篇 |
2010年 | 68篇 |
2009年 | 85篇 |
2008年 | 70篇 |
2007年 | 77篇 |
2006年 | 54篇 |
2005年 | 70篇 |
2004年 | 78篇 |
2003年 | 71篇 |
2002年 | 53篇 |
2001年 | 48篇 |
2000年 | 65篇 |
1999年 | 45篇 |
1998年 | 74篇 |
1997年 | 75篇 |
1996年 | 67篇 |
1995年 | 53篇 |
1994年 | 48篇 |
1993年 | 45篇 |
1992年 | 32篇 |
1991年 | 41篇 |
1990年 | 44篇 |
1989年 | 35篇 |
1988年 | 46篇 |
1987年 | 38篇 |
1986年 | 35篇 |
1985年 | 22篇 |
1984年 | 16篇 |
1983年 | 17篇 |
1982年 | 24篇 |
1980年 | 14篇 |
1979年 | 21篇 |
1976年 | 13篇 |
1975年 | 11篇 |
1974年 | 13篇 |
1973年 | 10篇 |
1972年 | 9篇 |
1971年 | 11篇 |
1967年 | 10篇 |
排序方式: 共有2194条查询结果,搜索用时 265 毫秒
1.
2.
3.
Ketai LH; Williamson MR; Telepak RJ; Levy H; Koster FT; Nolte KB; Allen SE 《Radiology》1994,191(3):665
4.
5.
A. Tentorio G. Ghilardi A. Pedroncelli R. Benco S. Stroppa S. Adib D. Gianola G. Pagani 《European journal of clinical pharmacology》1989,36(3):311-313
Summary The effect of nifedipine 40 mg·day–1 for 3 months on glucose tolerance, insulin and C-peptide secretion after an oral glucose tolerance test (OGTT), intra-venous glucose tolerance test (IVGTT) and glucagon stimulatory test, has been studied in 8 moderately hypertensive women suffering from non-insulin dependent diabetes mellitus (NIDDM).No significant variation in glucose metabolism was noted after nifedipine treatment, except for a slight improvement in insulin secretion after OGTT at the end of the study. There was an increase in cholesterol as a collateral effect. 相似文献
6.
7.
8.
Devang N Patel Francis D Pagani Todd M Koelling David B Dyke Ragavendra R Baliga Robert J Cody Kathleen D Lake Keith D Aaronson 《The Journal of heart and lung transplantation》2002,21(2):204-210
BACKGROUND: Pravastatin and simvastatin prolong survival and reduce transplant-related coronary vasculopathy, although low-density lipoprotein (LDL) lowering with these agents is only modest. The objective of this study was to assess the safety of moderate dose atorvastatin and its efficacy when prior treatment with another statin had failed to lower LDL to < 100 mg/dl. METHODS: Data from 185 patients were retrospectively evaluated for adverse events, duration of exposure (person-days), and the mean atorvastatin dose exposure. Changes in lipid parameters, and prednisone and cyclosporine doses were determined. RESULTS: Safety: 48 patients received atorvastatin for 24,240 person-days at a mean dose exposure of 21 +/- 10 mg. Rhabdomyolysis, myositis, myalgias, and hepatotoxicity occurred in 0, 2, 2, and 0 patients, respectively. All events occurred at the 10-mg dose, within the first 3 months, and were rapidly reversible with atorvastatin discontinuation. Efficacy: Thirty-four patients evaluable for efficacy analyses had a pre-atorvastatin LDL of 145 +/- 38 mg/dl on the following statins: pravastatin (n = 30, 40 +/- 0mg), fluvastatin (n = 3, 33 +/- 12 mg), simvastatin (n = 1, 40 mg). After atorvastatin (21 +/- 9 mg/day) for 133 +/- 67 days, LDL was reduced to 97 +/- 24 mg/dl (relative reduction 31 +/- 20%, p < 0.0001). At the end of the observation period (418 +/- 229 days, atorvastatin final dose 24 +/- 14 mg/day), LDL was further decreased to 88 +/- 23 mg (relative reduction 37 +/- 17%, p < 0.0001). CONCLUSION: Atorvastatin, when used at moderate doses and with close biochemical and clinical monitoring, appears to be safe and is effective in aggressively lowering LDL in heart transplant recipients when treatment with other statins has failed to achieve LDL goals. 相似文献
9.
10.
A. Pagani G. Ippoliti P. Perseghin C. Origlia L. Salvaneschi 《Annals of hematology》1988,56(3):103-105
Summary An unusual case of chronic myelocytic leukemia (CML) is described that presented leukocytosis at onset (720×109/l), symptoms of stasis, organomegaly, and a conspicuous infiltration of leukemic cells from the pelvis to the right popliteal cavity. As initial therapy and in addition to chemotherapy, six therapeutic leukapheresis treatments (TL) were performed and the patient showed dramatic symptomatic improvement with reduction in leukocytosis (97×109/l), organomegaly, and tissue infiltration. 相似文献